Antivascular Therapy for Epithelial Ovarian Cancer

Table 1

Ongoing studies with bevacizumab (BEV) in ovarian cancer.

Stage of the disease	Phase	Intervention	Trial number
Monotherapy
Recurrence after prior therapy with maintenance BEV	II	BEV monotherapy	NCT00866723
Combination with chemotherapy
Newly diagnosed	III	Carboplatin and paclitaxel with versus without BEV	ICON7NCT00483782
Previously untreated stage III or IV	III	Carboplatin and paclitaxel versus carboplatin, paclitaxel, and concurrent BEV with versus without extended BEV	GOG218NCT00262847
Adjuvant	II	Carboplatin, paclitaxel and BEV (BEV omitted in first cycle)	OVCANCT00129727
Newly diagnosed stage III/IV	II	Carboplatin, paclitaxel and BEV	AV53206sNCT00127920
Newly diagnosed stage IB-IV	II	Oxaliplatin and docetaxel with BEV	TEACONCT00296816
Newly diagnosed stage II-III	II	IV paclitaxel, IP cisplatin and IV BEV followed by BEV consolidation	AVF3953NCT00511992
Initial treatment of optimal stage II or III (adjuvant)	II	IV and IP paclitaxel, IP cisplatin, and IV BEV	06-064NCT00588237
Platinum-sensitive recurrent	III	Carboplatin and paclitaxel with versus without BEV followed by secondary cytoreduction surgery	GOG213NCT00565851
Platinum-sensitive recurrent	III	Carboplatin and gemcitabine with versus without BEV	AVF4095gNCT00434642
Platinum-sensitive recurrent	II	Gemcitabine, carboplatin and BEV	2005CO073NCT00267696
Platinum-sensitive recurrent	II	Carboplatin and liposomal doxorubicin plus BEV	CR015094NCT00698451
Platinum-sensitive recurrent	II	Oxaliplatin, gemcitabine, and BEV	DF 04-356NCT00418093
Recurrent having failed platinum- and taxane-based regimens	II	Pemetrexed and BEV	08-0508NCT00868192
Platinum-resistant recurrent	II	Weekly topotecan with BEV	AVF3648sNCT00343044
Platinum-resistant recurrent	II	BEV and docetaxel	MCC-14920NCT00504257
Platinum-resistant recurrent	II	BEV and carboplatin	2008-000878-20NCT00744718
Platinum-resistant recurrent	II	BEV and liposomal doxorubicin	AVF3910sNCT00846612
Platinum-resistant recurrent	II	Sequential BEV and metronomic cyclophosphamide	08-148NCT00856180
Platinum-resistant recurrent	II	BEV and albumin-bound paclitaxel	ALSSOPR0501NCT00407563
2nd or later complete remission, or untreated or refractory to platinum treatment or no response to salvage treatment	II	Stem-cell transplant trial evaluating treatment with BEV plus gemcitabine, docetaxel, melphalan, and carboplatin	2007-0368NCT00583622
Advanced peritoneal carcinomatosis	I	IP oxaliplatin and paclitaxel plus IV paclitaxel and BEV	2006-1068NCT00491855
Combination with other targeted therapies
Newly diagnosed	II	BEV and erlotinib as 1st line consolidation chemo after carboplatin, paclitaxel, and BEV induction therapy	07-039NCT00520013
Relapsed or refractory	II	BEV and erlotinib	UARIZ-05-0178-01NCT00696670
Recurrent or metastatic	II	BEV and erlotinib	NCI-6759NCT00126542
Refractory or recurrent	II	BEV and sorafenib	NCI-07-C-0058NCT00436215
Persistent or recurrent	II	BEV with or without everolimus	GOG-0186GNCT00886691

Studies were accessed from http://www.clinicaltrials.gov/ on May 17, 2009
IV = intravenous, IP = intraperitoneal